Osama Ishtiaq, Haider Z Baqai, Faiz Anwer,
Nisar Hussain
Medical Unit II, Holy Family
Hospital,
Background: There has been
little systematic study on the clinical spectrum of pancytopenia. This study
was done to describe the etiology, presentation and outcome of patients with
pancytopenia presenting in a general medical ward. Methods: Hundred
patients with pancytopenia were included in the study from October 2001 to
October 2002. Patients on cancer chemotherapy were excluded. Blood counts, bone
marrow examinations and trephine biopsies were performed according to standard
methods. Results: In
all cases, megaloblastic anemia constituted the largest group (n=39), and also
seen in conjunction with hemolytic anemia and septicemia. Hypersplenism secondary to portal
hypertension (cirrhosis) was the second most common diagnosis (n=19). Aplastic
anemia, septicemia and myelodysplasia were other common causes. Two patients
were the suspected cases of viral hemorrhagic fever. Thirteen (13%) patients
expired. Absolute neutrophil count (ANC) less than 500 /µl was seen in 14 (14%)
patients, among which 6 (15.3%) had megaloblastic anemia, 3 (37.5%) had
aplastic anemia, and 2 (40%) had myelodysplasia. Eleven patients with platelet
counts ≤ 10 x 109/L, 6 (54.5%) presented
with bleeding; and 2 of these 8 had aplastic anemia and 1 patient with
megaloblastic anemia. MCV values > 100fL and > 110fL were more frequent
in patients with megaloblastic anemia with most prominent anisopoikilocytosis,
microcytosis and fragmented RBCs. Macrocytosis was noted in 35 (89.7%) patients
with megaloblastic anemia and 12 (63.1%) with hypersplenism, 4 (50%) with
aplastic anemia. Hypersegmented neutrophils were noted in the
blood films of 36 (92.3%) patients with megaloblastic anemia. Conclusion: Megaloblastic
anemia, hypersplenism and aplastic anemia are the common causes of pancytopenia
in our study.
Keywords: Pancytopenia,
Megaloblastic Anemia, Hypersplenism, Aplastic Anemia
Pancytopenia means a disorder in which all 3 blood elements (red blood
cells, white blood cells and platelets) are decreased than normal.[1] Although it is a common clinical problem with an extensive differential
diagnosis, there is a relatively little discussion of this abnormality in major
textbooks of internal medicine and hematology.[2],[3] Pancytopenia can be due to decrease in hemaopoietic cell production in
the bone marrow e.g. by infections, toxins, malignant cell infiltration or
suppression or can have normocellular or even hypercellular marrow, without any
abnormal cells, e.g. ineffective hematopoiesis and dysplasia, maturation arrest
of all cell lines and peripheral sequestration of blood cells.[4]
Few clear recommendations can be found as to the
optimal investigative approach to pancytopenia. Some experts suggest that
marrow examination is essential to the diagnosis, but it has not been
established whether the procedure is necessary in all pancytopenic patients.1,2
Common questions that a healthcare professional asks
are 1) What are the most common causes of pancytopenia? and 2) What is the best
diagnostic approach to the pancytopenic patient? In the present study, we have
attempted to answer these questions by doing investigation of pancytopenic
patients in a general medical ward. Our study was limited by its restriction to
hospitalized patients. On the basis of our findings and available literature,
we have formulated a diagnostic approach to the problem of pancytopenia.
Pancytopenia was diagnosed in the presence of anemia
(hematocrit value <0.35 in women, <0.40 in men), leucopenia (WBC Ł 3.5 x 109/L) and thrombocytopenia (platelets < 150 x 109/L).
This
study was carried in Medical Unit II of Holy Family Hospital, Rawalpindi from
October 2001 to October 2002. All admitted patients with pancytopenia were
studied and a total of 100 adult patients were selected for the study by
non-probability convenient sampling. In all patients, a detailed relevant
history including the treatment history, history of drug intake, radiation
exposure, along with a physical examination of pallor, jaundice, hepatomegaly,
splenomegaly and lymphadenopathy, was taken.
Patients on cancer chemotherapy were excluded.
Blood
counts obtained prior to transfusion were done on an automated blood analyser
(Sysmex). In cases of very low counts, manual methods were used which included
total leucocyte count, red cell and platelet count, using improved Neubauer
chamber. Differential leucocyte count and red cell morphology was done manually
by staining the blood smears by May-Granwald-Giemsa stains. Bone marrow
aspiration and wherever required, a trephine biopsy were also performed. They
were independently reviewed by one investigator without knowledge of the
patient’s clinical presentation. Anisocytosis and poikilocytosis were graded
according to the degree of variation in size and shape.
Findings
of aspiration and trephine biopsies were interpreted in the light of history,
clinical examination and peripheral blood findings. Standard morphologic
criteria were used in diagnosis ([5],[6]). Bone marrow examination was done in 70
patients and 30 patients in whom bone marrow examination was not done were
either very ill or were meeting other criteria of diagnosis or expired before
the procedure.
Statistical methods
include descriptive statistics (mean, median, SD). Cross tabulation was carried
out to find out the correlation among different variables. Analysis was done on
SPSS v10 for windows.
The age of the patients ranged from 12 to 82 years with a mean age of
36.7 years, in which 53% were males. The
aetiological breakup of all patients is given in Table 1. Two patients were the
suspected cases of viral hemorrhagic fever (VHF) among which 1 patient was
diagnosed as having Cremean Congo hemorrhagic fever. Thirteen (13%) patients
expired, among which 8 patients had septicemia and disseminated intravascular
coagulation (DIC), 2 with VHF, 2 with disseminated malginancy and one with
acute leukemia. Two patients had a drug history of interferon and ribavarin.
Clinical features of patients with pancytopenia are
listed in Table 2. Patients with megaloblastic anemia had a mean age of 38.6
years and belong to almost all age groups. Similar ages (mean 35.6 years) are
seen in Aplastic Anemia as well. Patients with hypersplenism had a slightly
higher mean age of 41.37 years.
WBC counts did not vary between different diagnostic
categories. However, absolute neutrophil count (ANC) less than 500 /µl was seen
in 14 (14%) patients, among which 6 (15.3%) had megaloblastic anemia, 3 (37.5%)
had aplastic anemia, 2 (40%) had myelodysplasia and 1 (50%) with leukemia.
Platelet counts ≤ 10 x 109/L
were noted in 37.5% (n=3) of patients with aplastic anemia verus 7.6% (n=3) of
those with megaloblastic anemia. Of 11 patients with platelet counts ≤ 10
x 109/L, 6 (54.5%) presented with bleeding; and 2 of these
8 had aplastic anemia and 1 patient with megaloblastic anemia. Anemia was most
marked in patients with aplastic anemia,
acute leukemia and septicemia. (Figure 1). There was no marked variation
seen in the ESR among various diseases.
The MCV was ≥ 100fL in 41 patients (41%).
Highest MCV noted was 135fL seen in megaloblastic anemia. MCV values > 100fL
and > 110fL were more frequent in patients with megaloblastic anemia than in
those with aplastic anemia or hypersplenism (Figure 2). The MCV was < 100fL
in 6 (15.3%) patients with megaloblastic anemia (Figure 2). The lowest MCV was
58fL seen in iron deficiency anemia.
Moderate to marked anisopoikilocytosis, microcytosis
and fragmented RBCs were detected in all of the pancytopenic disorders, but
were most prominent in megaloblastic anemia (data not shown). Macrocytosis was
noted in 35 (89.7%) patients with megaloblastic anemia and 12 (63.1%) with
hypersplenism, 4 (50%) with aplastic anemia and 4 (80%) with myelodysplasia.
Microcytosis was seen in 3 (7.6%) patients with megaloblastic anemia, 7 (36.8%)
with hypersplenism, 1 (12.5%) with aplastic anemia and 1 (20%) in
myelodysplasia.
Hypersegmented neutrophils were noted in the blood films of 36 (92.3%) patients of 39 patients with megaloblastic anemia.
To calculate the sensitivity, specificity and
predictive values of blood findings for megaloblastic anemia, data were
examined for 100 pancytopenic patients whose diagnosis was established by
marrow examination or response to cobalamin and folate therapy (Table 3).
Neutrophil hypersegmentation had high specificity and predictive value for
megaloblastic anemia. In contrast, MCV > 110fL was specific but not
sensitive.
DISCUSSION
Pancytopenia is not an uncommon hematological problem encountered in our
clinical practice and should be suspected on clinical grounds when a patient
presents with unexplained anemia, prolonged fever and tendency to bleed. In all
cases, megaloblastic anemia constituted the largest group, and also seen in
conjunction with hemolytic anemia and septicemia. Hypersplenism secondary to portal
hypertension (cirrhosis) was the second most common diagnosis. Aplastic anemia,
septicemia and myelodysplasia were other common causes of pancytopenia (Table
1).
The approximately comparable series of pancytopenia is
from Savage et al2,
Iqbal et al4
and Qazi et al[7]. In all these studies, megaloblastic was found to be the largest cause
of pancytopenia. In contrast to local studies, significant contributor of
pancytopenia is HIV infections2,
compared to only 1 patient in our study. Study done by Iqbal et al also
included pediatric population and reported leishmaniasis in 4.8% of cases as
compared to none seen in our study.4
The major cause of megaloblastic anemia in our study is fever as 56.4% and chronic diarrhea (Table 2) as 38.5%. The percentage of chronic diarrhea in our study is not that common as in other studies.4,7
Table 1: Etiology of
Pancytopenia
|
Male |
Female |
Total |
Megaloblastic Anemia |
|
|
|
16 |
11 |
27 (27%) |
|
with Hemolytic
Anemia |
|
|
|
4 |
3 |
7 (7%) |
|
with Sepsis |
|
|
|
4 |
1 |
5 (5%) |
|
Total |
24 |
15 |
39 (39%) |
Hypersplenism |
|
|
|
With Cirrhosis |
|
|
|
6 |
6 |
12 (12%) |
|
With Chronic Malaria |
1 |
2 |
3 (3%) |
Undiagnosed |
1 |
3 |
4 (4%) |
Total |
8 |
11 |
19 (19%) |
Aplastic Anemia |
6 |
2 |
8 (8%) |
Myelodysplasia |
|
|
|
3 |
2 |
5 (5%) |
|
Septicemia and DIC |
|
|
|
3 |
2 |
5 (5%) |
|
Iron Deficiency Anemia with Leucopenia |
|
|
|
1 |
4 |
5 (5%) |
|
Connective Tissue Disease (SLE) |
|
|
|
- |
3 |
3 (3%) |
|
Disseminated Tuberculosis |
|
|
|
1 |
2 |
3 (3%) |
|
AIDS and Septicemia |
|
|
|
- |
1 |
1 (1%) |
|
Disseminated Malignancy |
|
|
|
2 |
- |
2 (2%) |
|
Hypoplastic Marrow |
|
|
|
1 |
1 |
2 (2%) |
|
Viral Hemorrhagic Fever (CCHF) |
|
|
|
- |
1 |
1 (1%) |
|
Acute Lymphocytic Leukemia |
|
|
|
1 |
- |
1 (1%) |
|
Mixed Leukemia |
|
|
|
- |
1 |
1 (1%) |
|
Undiagnosed |
|
|
|
3 |
2 |
5 (5%) |
|
Total |
|
|
|
53 |
47 |
100 |
|
Table 2.: Clinical Features of Patients presenting with Pancytopenia
(Percentages are calculated from totals of each disease)
Clinical Features |
Megaloblastic Anemia * |
Hypersplenism |
Aplastic Anemia |
Others ‡ |
Pallor |
100% |
100% |
100% |
100% |
Fever |
22
(56.4%) |
11
(57.4%) |
4
(50%) |
22 |
Diarrhea |
15
(38.5%) |
1
(5.3%) |
- |
6 |
Anorexia |
14
(35.9%) |
1
(5.3%) |
- |
4 |
Jaundice |
7
(17.9%) |
7
(36.8%) |
- |
2 |
Lymphadenopathy |
7
(17.9%) |
- |
1
(12.5%) |
8 |
Bleeding † |
12
(38.8%) |
8
(42.1%) |
4
(50%) |
9 |
Splenomegaly |
6
(15.4%) |
19
(100%) |
- |
9 |
Hepatomegaly |
7
(17.9%) |
4
(21.1%) |
- |
13 |
Dyspnea |
4
(10.3%) |
1
(5.3%) |
4
(50%) |
5 |
Weight Loss |
6
(15.4%) |
1
(5.3%) |
1
(12.5%) |
6 |
* Other causes with secondary megaloblastic anemia also included
† Upper GI Bleeding, Epistaxsis, Petechie,
Bleeding Gums are included
‡ Percentages not calculated because of different totals
Table 3: Sensitivity, Specificity
and Predictive Values for various laboratory findings in Diagnosis of
Megaloblastic Anemia in 100 pancytopenic patients *
Lab finding |
Sensitivity (%) |
Specificity (%) |
Positive Predictive Value (%) |
Negative Predictive Value (%) |
MCV > 100 fL |
82 |
91.8 |
86.4 |
88.8 |
MCV > 110 fL |
51.2 |
100 |
100 |
76.2 |
Neutrophil Hypersegmentation |
92.3 |
98.3 |
97.2 |
95.2 |
* Megaloblastic anemia
excluded in 61 patients by marrow examination or response to therapy
Figure 1: Box plots of
Hematocrit and Total leucocyte counts
(MA = Megaloblastic Anemia, HS
= Hypersplenism, AA = Aplastic Anemia)
Figure 2. Box plots of
Platelets and MCV
(MA = Megaloblastic Anemia, HS
= Hypersplenism, AA = Aplastic Anemia)
Pallor is present in all cases. All the patients were
empirically put on folate and cobalamin supplements with adequate clinical and
therapeutic response along with improvement of hematological parameters. In the
West, pancytopenia has become less common in patients with megaloblastic anemia2,
as only 13.7% of cases reported in a study done in New York.[8]
An interesting finding in our study is the raised MCV
above 100 fL in patients with megaloblastic anemia. Almost similar results were
seen in studies done by Savage et al2,
Iqbal et al4
and Qazi et al.7 Thirty seven patients had raised MCV above 100 fL,
and among them 32 (86.4%) were megaloblastic (Table 3). We can safely say that
diagnosis of megaloblastic anemia should be considered on top when MCV is above
100 fL. In contrast of our finding, normal MCV vales have been reported
previously in megaloblastic anemia 2,8
and ascribed to coexisting iron deficiency, chronic disease and hypersplenism.
Hypersegmentation of neutrophils is found as diagnostic to megaloblastic anemia
in our patients (Table 3). This demonstrates the value of peripheral blood film
in the differential diagnosis of pancytopenia. Although morphologic
abnormalities were almost invariable in patients with megaloblastic anemia,
these changes were often minimal or absent in patients with aplastic anemia,
leukemia and hypersplenism.
There is no significant variation seen in the age
groups of various diseases. Megaloblastic anemia is present in all age groups,
and similar is seen in aplastic anemia and hypersplenism. Two patients with
viral hemorrhagic fever (one confirmed), were present in younger age groups.
These patients developed DIC and pancytopenia, associated with septicemia. Both
expired due to excessive bleeding. Other patients having septicemia had varied
clinical presentations. We have seen that pancytopenia associated with
septicemia has worst prognosis. These findings are comparable with other
studies also.4,7
Hypersplenism is another commonest cause of
pancytopenia. In our study, hypersplenism (n=19) due to portal hypertension
(n=12) and chronic malaria (n=3) constituted the major group, however some
patients (4%) remained undiagnosed. These patients were later on treated for
tropical splenomegaly. Seventeen patients had positive anti-Hepatitis C virus
(HCV) antibodies, among them 12 (70.5%) had cirrhosis. In remaining patients
(29.5%), HCV as a cause of pancytopenia couldnot be ruled out. Suppression of
bone marrow by hepatitis C virus could be a possibility. This has been well
reported by Khokhar N[9] in his case reports, but we did not prove that.
Figure 3: A diagnostic approach to the pancytopenic patient;
PMN = polymorphonuclear neutrophil, TIBC = Total iron
binding Capacity,
Cbl = Cobalamin, HIV = human immunodeficiency virus,
ansiopoik = anisopoikilocytosis
Based on our findings and the
prior literature 1-3,5 we propose a diagnostic approach to
pancytopenic patients in our setup (Figure 3). These guidelines can be useful
for other centers as well. In all pancytopenic patients with neutrophil
hypersegmentation or abnormalities of erythrocyte morphology, serum Cobalamin
and folate measurements are indicated. Since these investigations are costly
therefore, it is recommended that in all these patients, a trial of vitamin
therapy should be given. A therapeutic response would include a rise in the
granulocyte, platelet and reticulocyte count within first 1 to 2 weeks of
treatment. Those patients with hypersegmented neutrophils, we suggest that bone
marrow examination and biopsy is generally unnecessary, but can be performed
later if there is no response to vitamin B12 and folate. Moreover,
marrow examination is also not indicated in pancytopenia secondary to
splenomegaly resulting from portal hypertension and with an unremarkable blood
film.
REFERENCES
1.
Firkin F, Chesterman C, Pennigton D, Rush B. De
Gruchy’s Clinical Hematology in Medical Practice. 5th ed. Oxford: Blackwell;
1989.
2.
Savage DG, Allen RH, Gangaidzo IT, Levy LM,
Gwanzura C, et. al. Pancytopenia in Zimbabwe. Am J Med Sci 1999
Jan;317(1):22-32.
3.
Rappeport JM, Bunn HF. Bone marrow failure:
aplastic anemia and other primary bone marrow disorders. In: Isselbacher KJ,
Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper KL, eds. Harrison’s
Priniciples of Internal Medicine. 13th ed. New York: McGraw-Hill; 1994:1754-7.
4.
Iqbal W, Hassan K, Ikram N, Nur S. Aetiological
breakup of 208 cases pancytopenia. J Rawal Med Coll 2001;5(1):7-9.
5.
Bain BJ, Clark DM, Lampert IA. Bone marrow
pathology. Oxford: Blackwell; 1992.
6.
Bain BJ. Blood Cells: A practical guide. 2nd ed.
Oxford: Blackwell; 1995.
7.
Qazi RA, Masood A. Diagnostic evaluation of
pancytopenia. J Rawal Med Coll 2002;6(1):30-3.
8.
Savage DG, Lindenbaum J, Stabler SP, Allen RH.
Serum methylmalonic acid and total homocysteine in the diagnosis of
deficiencies of cobalamin and folate. Am J Med 1994;96:239-46.
9.
Khokhar N. Bone marrow suppression in chronic
hepatitis C. Pakistan J Med Sci 2001;17(4):251-3
Address For Correspondence:
Dr. Osama Ishtiaq, 216-A, Street-13,
Gulzar-e-Quaid, Rawalpindi
Email:
osama@pakmedinet.com